Biosimilars [Design Issues]
Dear Helmut/all,
you wrote
Is there a specific reason why this is so? I mean, this sounds like the problem of having a sequence effect always occurs when having biosimilars. What is so "special" about them causing sequence (or carryover or trt*prd interaction) effects?
Thanks,
Ben
you wrote
❝ Although GLs consider cross-over studies the ‘Gold Standard’ in all (!) studies I have personally seen (and know of from other people as well) a significant sequence effect was observed. Maybe a parallel design is the better option.
Is there a specific reason why this is so? I mean, this sounds like the problem of having a sequence effect always occurs when having biosimilars. What is so "special" about them causing sequence (or carryover or trt*prd interaction) effects?
Thanks,
Ben
Complete thread:
- Biosimilars M.Vasu 2011-11-24 14:01
- Biosimilars Helmut 2011-11-24 14:44
- Biosimilars M.Vasu 2011-11-28 12:33
- Healthy subjects vs. patients Helmut 2011-11-28 12:56
- Biosimilars drgunasakaran1 2012-02-06 13:57
- BiosimilarsBen 2011-12-16 19:04
- Biosimilars M.Vasu 2011-11-28 12:33
- Biosimilars Chiku 2012-02-03 06:43
- Biosimilars drgunasakaran1 2012-02-10 11:33
- Biosimilars Chiku 2012-02-10 12:03
- Biosimilars Kumarnaidu2 2021-10-22 07:53
- Biosimilars Chiku 2012-02-10 12:03
- Biosimilars drgunasakaran1 2012-02-10 11:33
- Biosimilars Helmut 2011-11-24 14:44